Physician profile
Robert S Tucker
NPI 1205829710
$4,644.86
in general payments reported to CMS, 2019-2025
34 companies · $181 in 2025
The $181 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $925 · 2020: $810 · 2021: $1,104 · 2022: $506 · 2023: $573 · 2024: $545 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $679.01 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $651.48 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $583.82 | 2019-2023 | Otezla, Repatha, Evenity |
| Abbvie INC. | $541.76 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $329.86 | 2019-2022 | |
| Lilly USA, LLC | $242.53 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $209.07 | 2019-2021 | |
| Novo Nordisk INC | $182.07 | 2019-2024 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $148.16 | 2019-2022 | |
| Pfizer INC. | $145.33 | 2019-2025 | |
| Allergan, INC. | $134.76 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $72.55 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $65.82 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $62.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.35 | 2019-2024 | Jardiance |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $52.19 | 2021 | |
| Bausch Health US, LLC | $45.53 | 2021-2022 | |
| Horizon Therapeutics Plc | $41.57 | 2019-2021 | |
| Genentech USA, INC. | $39.77 | 2019-2020 | |
| Shire North American Group INC | $39.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.32 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.82 | 2021-2022 | |
| Kyowa Kirin, INC. | $33.20 | 2020 | |
| Esperion Therapeutics, INC. | $31.41 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.88 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $25.83 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $20.11 | 2021 | |
| Tris Pharma INC | $17.09 | 2023 | Dyanavel Xr |
| Seqirus USA INC | $16.34 | 2024 | Fluad, Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $15.69 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.25 | 2019 | |
| Nevro Corp. | $13.14 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.50 | 2021 | |
| Eisai INC. | $12.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Tucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.